Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19

Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19

BackgroundApproximately 13.8% and 6.1% of coronavirus disease 2019 (COVID-19) patients require hospitalization and sometimes intensive care unit (ICU) admission, respectively. There is no biomarker to predict which of these patients will develop an aggressive stage that we could improve their qualit...

Full description

Bibliographic Details
Main Authors: Silvia Martínez-Diz, Fernando Marín-Benesiu, Ginesa López-Torres, Olivia Santiago, José F. Díaz-Cuéllar, Sara Martín-Esteban, Ana I. Cortés-Valverde, Verónica Arenas-Rodríguez, Sergio Cuenca-López, Patricia Porras-Quesada, Carmen Ruiz-Ruiz, Ana C. Abadía-Molina, Carmen Entrala-Bernal, Luis J. Martínez-González, Maria Jesus Álvarez-Cubero
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
biomarkers
cytometry
COVID-19
SNPs
CyTOF
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1094644/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1094644/full

Similar Items